Serial 79435549

Live / Registered — Registered (as of 21 Apr 2026)

What this means for you

Registered since 21 Apr 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 21 Apr 2032: the §71 affidavit of use).

Record

Serial number
79435549
Registration number
8217704
Mark type
Design / logo
Filed
24 Sept 2025
Published for opposition
03 Mar 2026
Registered
21 Apr 2026
Next maintenance filing
§71 affidavit of use, due by 21 Apr 2032 (grace period to 21 Oct 2032)
Attorney of record
Ben Natter

Goods and services

  • Class 001 — Chemicals: Chemicals for use in industry and science; biochemicals, namely, polypeptides and engineered antibodies for scientific, laboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating or G-protein-coupled receptor modulating engineered antibodies for scientific, laboratory or research purposes; ion channel modulating or G-protein-coupled receptor modulating engineered antibodies for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs
  • Class 005 — Pharmaceuticals: Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activity, including preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; drugs, namely, pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activity, including those for use in the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; engineered antibodies for medical use; pharmaceuticals, drugs and pharmaceutical preparations incorporating engineered antibodies, ion channel modulating or G-protein-coupled receptor modulating engineered antibodies or engineered antibodies derived from mini-protein toxins; vaccines
  • Class 042 — Scientific and technological services: Scientific and technological services, namely scientific research, analysis and testing in the fields of pharmaceuticals, biochemicals, polypeptides, antibodies, ion channel modulating or G-protein-coupled receptor modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; scientific and medical research laboratory services relating to the production of antibodies, ion channel modulating or G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid
  • Class 044 — Medical, beauty and agricultural services: Medical services; medical testing, analysis and diagnostic services in the field of antibodies; medical services connected with the treatment of diseases through the use of antibodies, ion channel blocking antibodies or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid

Owner

Prosecution history

  • 15 Oct 2026 — FINAL DECISION TRANSACTION PROCESSED BY IB
  • 27 Sept 2026 — FINAL DISPOSITION NOTICE SENT TO IB
  • 27 Sept 2026 — FINAL DISPOSITION PROCESSED
  • 21 Jul 2026 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
  • 21 Apr 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
  • 21 Apr 2026 — REGISTERED-PRINCIPAL REGISTER
  • 03 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 03 Mar 2026 — PUBLISHED FOR OPPOSITION
  • 25 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 07 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 05 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 05 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 05 Feb 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
  • 01 Jan 2026 — REFUSAL PROCESSED BY IB
  • 18 Dec 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

View this trademark record on Rightsy